Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.56 |
| ▸ | DNMT3A | Q9Y6K1 | 2/20 | 0.56 |
| ▸ | DNMT3L | Q9UJW3 | 1/20 | 0.56 |
| ▸ | ACLY | P53396 | 1/20 | 0.55 |
| ▸ | NSD2 | O96028 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.53 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.53 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | PRKCI | P41743 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7784318 | 0.88 | DNMT1 (0.65) | CYP3A4CYP2C9USP2HTTL3MBTL1 | |
| SCHEMBL4601893 | 0.81 | GRM4 (0.62) | TDP1MEN1KMT2AALDH1A1GAA | |
| SCHEMBL7082250 | 0.81 | NAMPT (0.51) | CYP3A4USP2HTTL3MBTL1DNMT1 | |
| SCHEMBL7479594 | 0.81 | CYP2C9 (0.62) | CYP3A4CYP2C9L3MBTL1DNMT1DNMT3A | |
| SCHEMBL27519785 | 0.81 | ITGB1 (0.61) | CYP3A4CYP2C9DNMT1DNMT3ADNMT3L | |
| SCHEMBL6626851 | 0.81 | ITGB1 (0.61) | CYP3A4CYP2C9DNMT1DNMT3ADNMT3L | |
| SCHEMBL804472 | 0.81 | CYP3A4 (0.50) | CYP3A4L3MBTL1DNMT1DNMT3ADNMT3L | |
| SCHEMBL8573837 | 0.80 | NSD2 (0.56) | NSD2NR2E1 | |
| SCHEMBL5603305 | 0.80 | NSD2 (0.56) | NSD2ALDH1A1GAA | |
| SCHEMBL29375172 | 0.79 | KDM4E (0.56) | L3MBTL1NSD2TDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119350240-A | 4-Quinoline anilines main protease inhibitor and preparation method and medical application thereof | 河南师范大学 | 2025-01-24 | — | — | CN | claimed |
| WO-2026022286-A1 | N-PHENYL-QUINOLINE-4-CARBOXAMIDE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Institut National de la Santé et de la Recherche Médicale (FR) | 2026-01-29 | — | — | WO | disclosed |
| CN-119350240-A | 4-Quinoline anilines main protease inhibitor and preparation method and medical application thereof | 河南师范大学 | 2025-01-24 | — | — | CN | disclosed |
| US-10633369-B2 | Method of inhibiting DYRK1B | 4 SC AG (DE) | 2020-04-28 | — | — | US | disclosed |
| US-20180201606-A1 | METHOD OF INHIBITING DYRK1B | 4 SC AG (DE) | 2018-07-19 | — | — | US | disclosed |
| US-9951050-B2 | Method of inhibiting DYRK1B | 4 SC AG (DE) | 2018-04-24 | — | — | US | disclosed |
| US-20140371251-A1 | METHOD OF INHIBITING DYRK1B | 4SC DISCOVERY GMBH (DE) | 2014-12-18 | — | — | US | disclosed |
| EP-2408766-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Schering Corporation (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| WO-2004087669-A1 | NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO. LTD. (JP) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633369-B2 | Method of inhibiting DYRK1B | SMO, GLI1, GRK2 | CYP3A4 4854/4885CYP2C9 4856/4885USP2 1790/4885 |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | CYP3A4 284/4885CYP2C9 1178/4885USP2 3448/4885 |
| US-20180201606-A1 | METHOD OF INHIBITING DYRK1B | SMO, GLI1, GRK2 | CYP3A4 4854/4885CYP2C9 4856/4885USP2 1790/4885 |
| US-20140371251-A1 | METHOD OF INHIBITING DYRK1B | SMO, GLI1, GRK2 | CYP3A4 4854/4885CYP2C9 4856/4885USP2 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.